Chemins
This article was originally published in The Tan Sheet
Executive Summary
Dietary supplement manufacturer and its founder and president entered not guilty pleas in Denver federal court Nov. 9 to charges of product misbranding, conspiracy, making false statements, aiding and abetting, and obstructing FDA's investigation into the firm's alleged use of pharmaceutical-grade ephedrine and caffeine in its products. No trial date has been set. A grand jury on Oct. 21 returned a 14-count indictment against the company and exec James Cameron related to the manufacture of Formula One supplements with ma huang and kola nut (1"The Tan Sheet" Oct. 25, p. 5)
You may also be interested in...
Chemins
July sentencing scheduled for dietary supplement manufacturer and its founder and president, who pleaded guilty Jan. 6 to charges of conspiring to hide use of ephedrine hydrochloride and caffeine anhydrous from the FDA. In exchange for the plea, the U.S. Attorney agrees to dismiss the remaining counts of the indictment, including product misbranding; making false statements; aiding and abetting; and obstructing FDA's investigation into the firm's alleged use of pharmaceutical-grade ephedrine and caffeine in supplements. Chemins and exec James Cameron originally entered not guilty pleas in Denver federal court Nov. 9 (1"The Tan Sheet" Nov. 15, 1999, In Brief)
Chemins
July sentencing scheduled for dietary supplement manufacturer and its founder and president, who pleaded guilty Jan. 6 to charges of conspiring to hide use of ephedrine hydrochloride and caffeine anhydrous from the FDA. In exchange for the plea, the U.S. Attorney agrees to dismiss the remaining counts of the indictment, including product misbranding; making false statements; aiding and abetting; and obstructing FDA's investigation into the firm's alleged use of pharmaceutical-grade ephedrine and caffeine in supplements. Chemins and exec James Cameron originally entered not guilty pleas in Denver federal court Nov. 9 (1"The Tan Sheet" Nov. 15, 1999, In Brief)
Chemins
July sentencing scheduled for dietary supplement manufacturer and its founder and president, who pleaded guilty Jan. 6 to charges of conspiring to hide use of ephedrine hydrochloride and caffeine anhydrous from the FDA. In exchange for the plea, the U.S. Attorney agrees to dismiss the remaining counts of the indictment, including product misbranding; making false statements; aiding and abetting; and obstructing FDA's investigation into the firm's alleged use of pharmaceutical-grade ephedrine and caffeine in supplements. Chemins and exec James Cameron originally entered not guilty pleas in Denver federal court Nov. 9 (1"The Tan Sheet" Nov. 15, 1999, In Brief)